anti-CD40

Anti-CD40 refers to a class of monoclonal antibodies designed to target the CD40 receptor, a key co-stimulatory molecule and member of the tumor necrosis factor receptor (TNFR) superfamily. CD40 is expressed on the surface of various immune cells, most notably professional antigen-presenting cells (APCs) such as dendritic cells, B cells, and macrophages. In the context of oncology, anti-CD40 antibodies typically function as agonists, mimicking the action of the natural CD40 ligand (CD154). This binding triggers APC maturation and activation, leading to the upregulation of MHC molecules and co-stimulatory markers (e.g., CD80, CD86), as well as the secretion of pro-inflammatory cytokines like IL-12 and IFN-gamma. This process, often termed "licensing" of dendritic cells, is crucial for the priming and expansion of tumor-specific cytotoxic T cells. Preclinical and clinical research suggests that anti-CD40 therapy can reprogram the suppressive tumor microenvironment, shifting macrophage polarization from an M2-like inhibitory phenotype to an M1-like effector phenotype. It is frequently investigated in combination with chemotherapy, radiotherapy, or immune checkpoint inhibitors to enhance therapeutic efficacy in refractory or poorly immunogenic tumors, such as melanoma and pancreatic cancer. Engineering strategies, such as conjugation to extracellular matrix-binding peptides, are also being explored to localize the antibody's activity and reduce systemic toxicity.

Other names

CD40 agonistCD-40 agonistCD 40 agonistanti-CD40 antibodyanti-CD-40 antibodyanti-CD 40 antibodyαCD40agonist anti-CD40